Literature DB >> 12270123

Delayed treatment with doxycycline has limited effect on anthrax infection in BLK57/B6 mice.

John Kalns1, Julie Morris, Jeffrey Eggers, Johnathan Kiel.   

Abstract

Blk57/B6 mice were infected with LD90 dose of Sterne strain anthrax spores subcutaneously and then treated with doxycycline. Doxycycline at a dose of 1.5mg/kg, by intra-peritoneal injection, protected mice from death when given at the same time as spores. When doxycycline administration was delayed 4h survival is 90%. Delay of 24h increased survival time but had no impact on eventual mortality. When doxycycline was delayed 48h, mortality and time to death were comparable to sham injection. Peritoneal macrophages harvested from Blk57/B6 mice were examined for response to anthrax lethal toxin and are shown to be deficient in their ability to produce TNF-alpha and have increased expression of IL-6 compared to RAW 264.7 murine macrophage cell line. These findings suggest that antibiotic therapy has limited effects following lethal anthrax spore challenge, even when the host is of a phenotype that does not produce TNF-alpha in response to anthrax lethal toxin exposure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270123     DOI: 10.1016/s0006-291x(02)02226-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Efficient growth inhibition of Bacillus anthracis by knocking out the ribonucleotide reductase tyrosyl radical.

Authors:  Eduard Torrents; Margareta Sahlin; Daniele Biglino; Astrid Gräslund; Britt-Marie Sjöberg
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-01       Impact factor: 11.205

Review 2.  The Bacillus cereus Group: Bacillus Species with Pathogenic Potential.

Authors:  Monika Ehling-Schulz; Didier Lereclus; Theresa M Koehler
Journal:  Microbiol Spectr       Date:  2019-05

3.  Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.

Authors:  H S Heine; S V Shadomy; A E Boyer; L Chuvala; R Riggins; A Kesterson; J Myrick; J Craig; M G Candela; J R Barr; K Hendricks; W A Bower; H Walke; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

4.  Modeling the host response to inhalation anthrax.

Authors:  Judy Day; Avner Friedman; Larry S Schlesinger
Journal:  J Theor Biol       Date:  2011-02-03       Impact factor: 2.691

5.  A mathematical simulation of the inflammatory response to anthrax infection.

Authors:  Rukmini Kumar; Carson C Chow; John D Bartels; Gilles Clermont; Yoram Vodovotz
Journal:  Shock       Date:  2008-01       Impact factor: 3.454

6.  mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia.

Authors:  Thomas R Kozel; William J Murphy; Suzanne Brandt; Bruce R Blazar; Julie A Lovchik; Peter Thorkildson; Ann Percival; C Rick Lyons
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-29       Impact factor: 11.205

7.  Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice.

Authors:  Mahtab Moayeri; Diana Haines; Howard A Young; Stephen H Leppla
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.